159 related articles for article (PubMed ID: 22964958)
1. Pilot study of aprepitant for prevention of post-ERCP pancreatitis in high risk patients: a phase II randomized, double-blind placebo controlled trial.
Shah TU; Liddle R; Branch MS; Jowell P; Obando J; Poleski M
JOP; 2012 Sep; 13(5):514-8. PubMed ID: 22964958
[TBL] [Abstract][Full Text] [Related]
2. Rectal indometacin dose escalation for prevention of pancreatitis after endoscopic retrograde cholangiopancreatography in high-risk patients: a double-blind, randomised controlled trial.
Fogel EL; Lehman GA; Tarnasky P; Cote GA; Schmidt SE; Waljee AK; Higgins PDR; Watkins JL; Sherman S; Kwon RSY; Elta GH; Easler JJ; Pleskow DK; Scheiman JM; El Hajj II; Guda NM; Gromski MA; McHenry L; Arol S; Korsnes S; Suarez AL; Spitzer R; Miller M; Hofbauer M; Elmunzer BJ;
Lancet Gastroenterol Hepatol; 2020 Feb; 5(2):132-141. PubMed ID: 31780277
[TBL] [Abstract][Full Text] [Related]
3. High-dose allopurinol for prevention of post-ERCP pancreatitis: a prospective randomized double-blind controlled trial.
Katsinelos P; Kountouras J; Chatzis J; Christodoulou K; Paroutoglou G; Mimidis K; Beltsis A; Zavos C
Gastrointest Endosc; 2005 Mar; 61(3):407-15. PubMed ID: 15758912
[TBL] [Abstract][Full Text] [Related]
4. Suppository naproxen reduces incidence and severity of post-endoscopic retrograde cholangiopancreatography pancreatitis: Randomized controlled trial.
Mansour-Ghanaei F; Joukar F; Taherzadeh Z; Sokhanvar H; Hasandokht T
World J Gastroenterol; 2016 Jun; 22(21):5114-21. PubMed ID: 27275104
[TBL] [Abstract][Full Text] [Related]
5. Ulinastatin for pancreatitis after endoscopic retrograde cholangiopancreatography: a randomized, controlled trial.
Tsujino T; Komatsu Y; Isayama H; Hirano K; Sasahira N; Yamamoto N; Toda N; Ito Y; Nakai Y; Tada M; Matsumura M; Yoshida H; Kawabe T; Shiratori Y; Omata M
Clin Gastroenterol Hepatol; 2005 Apr; 3(4):376-83. PubMed ID: 15822043
[TBL] [Abstract][Full Text] [Related]
6. Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial.
Andriulli A; Clemente R; Solmi L; Terruzzi V; Suriani R; Sigillito A; Leandro G; Leo P; De Maio G; Perri F
Gastrointest Endosc; 2002 Oct; 56(4):488-95. PubMed ID: 12297762
[TBL] [Abstract][Full Text] [Related]
7. Results of the Tokyo trial of prevention of post-ERCP pancreatitis with risperidone-2: a multicenter, randomized, placebo-controlled, double-blind clinical trial.
Uchino R; Isayama H; Tsujino T; Sasahira N; Ito Y; Matsubara S; Takahara N; Arizumi T; Toda N; Mohri D; Togawa O; Yagioka H; Yanagihara Y; Nakajima K; Akiyama D; Hamada T; Miyabayashi K; Mizuno S; Kawakubo K; Kogure H; Sasaki T; Yamamoto N; Nakai Y; Hirano K; Tada M; Koike K
Gastrointest Endosc; 2013 Dec; 78(6):842-850. PubMed ID: 23910063
[TBL] [Abstract][Full Text] [Related]
8. Somatostatin for prevention of post-ERCP pancreatitis: a randomized, double-blind trial.
Concepción-Martín M; Gómez-Oliva C; Juanes A; Díez X; Prieto-Alhambra D; Torras X; Sainz S; Villanueva C; Farre A; Guarner-Argente C; Guarner C
Endoscopy; 2014 Oct; 46(10):851-6. PubMed ID: 24977398
[TBL] [Abstract][Full Text] [Related]
9. Oral udenafil and aceclofenac for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients: a randomized multicenter study.
Lee TY; Choi JS; Oh HC; Song TJ; Do JH; Cheon YK
Korean J Intern Med; 2015 Sep; 30(5):602-9. PubMed ID: 26354054
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of recombinant platelet-activating factor acetylhydrolase for reducing the incidence and severity of post-ERCP acute pancreatitis.
Sherman S; Alazmi WM; Lehman GA; Geenen JE; Chuttani R; Kozarek RA; Welch WD; Souza S; Pribble J;
Gastrointest Endosc; 2009 Mar; 69(3 Pt 1):462-72. PubMed ID: 19231487
[TBL] [Abstract][Full Text] [Related]
11. Randomized controlled trial of pancreatic stenting to prevent pancreatitis after endoscopic retrograde cholangiopancreatography.
Kawaguchi Y; Ogawa M; Omata F; Ito H; Shimosegawa T; Mine T
World J Gastroenterol; 2012 Apr; 18(14):1635-41. PubMed ID: 22529693
[TBL] [Abstract][Full Text] [Related]
12. The prophylactic effect of somatostatin on post-therapeutic endoscopic retrograde cholangiopancreatography pancreatitis: a randomized, multicenter controlled trial.
Lee KT; Lee DH; Yoo BM
Pancreas; 2008 Nov; 37(4):445-8. PubMed ID: 18953260
[TBL] [Abstract][Full Text] [Related]
13. Low-molecular-weight heparin does not prevent acute post-ERCP pancreatitis.
Rabenstein T; Fischer B; Wiessner V; Schmidt H; Radespiel-Tröger M; Hochberger J; Mühldorfer S; Nusko G; Messmann H; Schölmerich J; Schulz HJ; Schönekäs H; Hahn EG; Schneider HT
Gastrointest Endosc; 2004 May; 59(6):606-13. PubMed ID: 15114301
[TBL] [Abstract][Full Text] [Related]
14. Rectal indomethacin versus placebo to reduce the incidence of pancreatitis after endoscopic retrograde cholangiopancreatography: results of a controlled clinical trial.
Andrade-Dávila VF; Chávez-Tostado M; Dávalos-Cobián C; García-Correa J; Montaño-Loza A; Fuentes-Orozco C; Macías-Amezcua MD; García-Rentería J; Rendón-Félix J; Cortés-Lares JA; Ambriz-González G; Cortés-Flores AO; Alvarez-Villaseñor Adel S; González-Ojeda A
BMC Gastroenterol; 2015 Jul; 15():85. PubMed ID: 26195123
[TBL] [Abstract][Full Text] [Related]
15. Rectal Indomethacin Does Not Prevent Post-ERCP Pancreatitis in Consecutive Patients.
Levenick JM; Gordon SR; Fadden LL; Levy LC; Rockacy MJ; Hyder SM; Lacy BE; Bensen SP; Parr DD; Gardner TB
Gastroenterology; 2016 Apr; 150(4):911-7; quiz e19. PubMed ID: 26775631
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of postprocedure administration of gabexate mesylate in the prevention of post-ERCP pancreatitis: a randomized, controlled, multicenter study.
Manes G; Ardizzone S; Lombardi G; Uomo G; Pieramico O; Porro GB
Gastrointest Endosc; 2007 Jun; 65(7):982-7. PubMed ID: 17531632
[TBL] [Abstract][Full Text] [Related]
17. A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis.
Elmunzer BJ; Scheiman JM; Lehman GA; Chak A; Mosler P; Higgins PD; Hayward RA; Romagnuolo J; Elta GH; Sherman S; Waljee AK; Repaka A; Atkinson MR; Cote GA; Kwon RS; McHenry L; Piraka CR; Wamsteker EJ; Watkins JL; Korsnes SJ; Schmidt SE; Turner SM; Nicholson S; Fogel EL;
N Engl J Med; 2012 Apr; 366(15):1414-22. PubMed ID: 22494121
[TBL] [Abstract][Full Text] [Related]
18. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
[TBL] [Abstract][Full Text] [Related]
19. Can somatostatin prevent post-ERCP pancreatitis? Results of a randomized controlled trial.
Arvanitidis D; Anagnostopoulos GK; Giannopoulos D; Pantes A; Agaritsi R; Margantinis G; Tsiakos S; Sakorafas G; Kostopoulos P
J Gastroenterol Hepatol; 2004 Mar; 19(3):278-82. PubMed ID: 14748874
[TBL] [Abstract][Full Text] [Related]
20. Is prophylactic somatostatin effective to prevent post-endoscopic retrograde cholangiopancreatography pancreatitis or hyperamylasemia? A randomized, placebo-controlled pilot trial.
Wang ZK; Yang YS; Cai FC; Wang YH; Shi XL; Ding C; Li W
Chin Med J (Engl); 2013 Jul; 126(13):2403-8. PubMed ID: 23823808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
